ClinicalTrials.gg
Not yet recruitingNCT07675954MDR-ENDPlusUpdated Jun 30, 2026

A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis

A Phase 3 interventional study of MDR-END Plus regimen and Standard-of-care (SoC) treatment in Rifampicin-Resistant Tuberculosis, sponsored by Seoul National University Hospital. Not yet recruiting at 2 sites in South Africa. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Seoul National University Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa — 7 open to participants now, 8 under way, 3 of them phase 3. Tuberculosis, Multidrug-Resistant · South Africa.

Planned enrollment
15th of 37
294 · median 248
Started
2026
with 2 others
Phase 3
11 of 46
2 open now
Registered
46th of 46
by date

Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 3, and was the 46th registered.

Tuberculosis, Multidrug-Resistant

132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.

Browse Tuberculosis, Multidrug-Resistant studies →

Open to participants now

7 of the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, or all of them as a file.
02

Study summary

This is a phase 3, open-label, randomized clinical trial in adults and adolescents aged 15 years or older who need treatment for rifampicin-resistant tuberculosis in South Africa.

The goal of this clinical trial is to learn whether a 6-month MDR-END Plus regimen works as well as current standard of care (SoC) treatment for rifampicin-resistant tuberculosis. The trial will also learn whether the MDR-END Plus regimen is safer and easier to tolerate than SoC regimens.

The main questions this trial aims to answer are:

  • Does the MDR-END Plus regimen lead to a favorable treatment outcome 12 months after treatment is stopped, compared with SoC regimens?
  • Do participants receiving the MDR-END Plus regimen have fewer important safety or tolerability problems during treatment and up to 90 days after treatment is stopped, compared with SoC regimens?

Researchers will compare the MDR-END Plus regimen with South African standard of care (SoC) treatment for rifampicin-resistant tuberculosis.

Participants will:

  • Be randomly assigned to receive either the MDR-END Plus regimen or SoC treatment.
  • Take tuberculosis medicines for about 6 months, although treatment may be extended in some cases.
  • Attend study visits during treatment and after treatment is stopped.
  • Have clinical assessments, blood tests, heart tracing tests, vision and nerve assessments, and tuberculosis tests.
  • Be followed for 12 months after treatment is stopped.
Read the detailed description

This is a phase 3, multi-site, open-label, randomized controlled trial conducted in South Africa. The study will enroll adults and adolescents aged 15 years or older who require treatment for pulmonary rifampicin-resistant tuberculosis.

Participants will be randomized in a 1:1 ratio to either the investigational arm or the control arm. Randomization will be stratified by study site and HIV status. The study is open-label because participants and investigators will know which treatment is assigned.

Participants in the investigational arm will receive the MDR-END Plus regimen, consisting of bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide. Regimen adaptations may be made according to the drug susceptibility profile of the participant's Mycobacterium tuberculosis strain and drug suitability. Treatment may be extended according to protocol-defined criteria.

Participants in the control arm will receive South African standard of care (SoC) treatment for rifampicin-resistant tuberculosis according to national guidance and site practice.

Participants will attend study visits during treatment and after treatment discontinuation. Study assessments will include clinical evaluations, safety laboratory tests, electrocardiograms, microbiological assessments, and protocol-specified safety and tolerability assessments. Participants will be followed for 12 months after treatment discontinuation.

The primary efficacy analysis will assess whether the MDR-END Plus regimen is non-inferior to SoC regimens for favorable treatment outcome at 12 months after treatment discontinuation. The co-primary safety and tolerability analysis will assess whether the MDR-END Plus regimen is superior to SoC regimens during treatment and up to 90 days after treatment discontinuation, contingent upon demonstration of efficacy non-inferiority.

03

Conditions studied

  • Rifampicin-Resistant Tuberculosis

Keywords

  • Rifampicin-resistant tuberculosis
  • Multidrug-resistant tuberculosis
  • MDR-TB
  • RR-TB
  • Bedaquiline
  • Delamanid
  • Delpazolid
  • Levofloxacin
  • Pyrazinamide
  • MDR-END Plus
  • Short treatment regimen
  • South Africa
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to voluntarily provide written to participate in the study prior to initiation of any study-related procedures. For participants under the age of 18 years, signed consent may be obtained from the child's biological parent, legal guardian, or primary caregiver in the presence of the child. Minor participants must also be willing to provide written assent for study participation.
  2. To the best of their knowledge and abilities at screening, participants must be willing and able to adhere to the complete follow-up schedule and all study procedures.
  3. Male or female participants aged 15 years or older.
  4. Participant requires treatment for pulmonary rifampicin-resistant tuberculosis based on one or more of the following:

    • Documented molecular drug susceptibility testing, such as TB nucleic acid amplification test, line probe assay, targeted next-generation sequencing, or culture-based phenotypic drug susceptibility testing on a sample obtained from the participant within 8 weeks prior to screening, even if rifampicin resistance is not re-confirmed on a sample obtained at screening; or
    • Documented or self-reported clinical symptoms or signs of pulmonary tuberculosis disease, with or without radiological changes consistent with pulmonary tuberculosis, and evidence of close contact with someone with confirmed rifampicin-resistant tuberculosis which, in the opinion of the site investigator, indicates significant exposure and a clinical decision has been made to treat the participant for rifampicin-resistant tuberculosis in routine care; or
    • Documented peripheral tuberculosis lymphadenitis or tuberculosis pleurisy with confirmed rifampicin-resistant Mycobacterium tuberculosis on lymph node or pleural fluid aspiration, along with documented symptoms or signs suggestive of pulmonary tuberculosis without culture confirmation.
  5. Not yet started rifampicin-resistant tuberculosis treatment, or initiated rifampicin-resistant tuberculosis treatment in routine care within 10 days prior to enrolment.
  6. Body weight of at least 30 kg.
  7. Documented status and/or willing to undergo HIV testing.
  8. Participants living with HIV must be on antiretroviral therapy, or due to start antiretroviral therapy within 2 months of enrolment, regardless of , provided they are clinically stable in the opinion of the site investigator.
  9. Pregnant women in any trimester and breastfeeding women are eligible for inclusion.

Exclusion criteria

Exclusion Criteria:

  1. Two or more of the following four drug groups cannot be used: bedaquiline or clofazimine; delamanid or pretomanid; linezolid or delpazolid; levofloxacin or moxifloxacin, due to any of the following:

    • Documented Mycobacterium tuberculosis resistance in the current or prior treatment episode;
    • Prior exposure of 1 month or longer, unless protocol-defined exceptions are met;
    • Absolute to the relevant study drugs;
    • Use of prohibited concomitant medications within 14 days prior to enrolment.
  2. Ongoing treatment for rifampicin-resistant tuberculosis for more than 10 days in the current tuberculosis episode.
  3. Isolated extrapulmonary tuberculosis without pulmonary involvement.
  4. Extrapulmonary tuberculosis, with or without concurrent pulmonary tuberculosis, involving the central nervous system, osteoarticular sites, pericardium, or disseminated/miliary disease.
  5. Any of the following laboratory or abnormalities:

    A. or aspartate transaminase >120 U/L; B. Total >2.4 mg/dL; C. Estimated by the CKD-EPI equation \<30 mL/min/1.73 m²; D. Serum potassium \<3.2 mmol/L; E. >480 msec.

  6. Atrioventricular block, second or third degree; current or previous history of ventricular arrhythmias or long QT syndrome; or family history of long QT syndrome or sudden cardiac death.
  7. Any condition or circumstance which, in the opinion of the investigator, based on information available at the time of screening, raises concerns regarding the participant's safety or ability to participate in the trial or the integrity of the study data.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
294 participants (estimated)

Study arms

  • Experimental
    Investigational arm

    Participants assigned to the investigational arm will receive the 6-month MDR-END Plus regimen, consisting of bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide, with protocol-defined modifications based on drug susceptibility and drug suitability. Treatment may be extended up to 9 months according to protocol-defined criteria.

    Drug: MDR-END Plus regimen

  • Active comparator
    Control arm

    Participants assigned to the control arm will receive standard of care (SoC) treatment for rifampicin-resistant tuberculosis according to South African national guidance and site practice.

    Drug: Standard-of-care (SoC) treatment

Interventions

  • DrugMDR-END Plus regimen

    The investigational MDR-END Plus regimen consists of oral anti-tuberculosis drugs including bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide. Dosing and duration will follow the study protocol, with modifications based on body weight, drug susceptibility, drug suitability, and protocol-defined treatment extension criteria.

    Also known as: Bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide

  • DrugStandard-of-care (SoC) treatment

    Participants in the control arm will receive South African standard-of-care treatment for rifampicin-resistant tuberculosis according to national treatment guidance and site practice. The regimen may vary according to drug susceptibility results, drug suitability, and clinical judgement.

    Also known as: South African standard of care treatment

06

What researchers measure

Primary outcomes

  1. Favourable outcome at 12 months after treatment discontinuation

    Proportion of evaluable participants with a favourable outcome at 12 months after treatment discontinuation in the investigational arm compared with the control arm. The primary efficacy analysis will assess whether the MDR-END Plus regimen is non-inferior to SoC regimens.

    Time frame: 12 months after treatment discontinuation

  2. Composite safety and tolerability endpoint

    Proportion of evaluable participants meeting the predefined composite safety and tolerability endpoint during treatment and up to 90 days after treatment discontinuation in the investigational arm compared with the control arm. The co-primary safety and tolerability analysis will assess whether the MDR-END Plus regimen is superior to SoC regimens, contingent upon demonstration of efficacy non-inferiority. The composite endpoint includes protocol-defined adverse events, serious adverse events, adverse events of special interest, and adverse events leading to permanent discontinuation of any study drug.

    Time frame: During treatment and up to 90 days after treatment discontinuation

Secondary outcomes

  1. Model-derived delpazolid AUC0-24

    Model-derived delpazolid area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) will be estimated from the final population pharmacokinetic model in participants receiving the MDR-END Plus regimen. This exposure metric will be used to support dose evaluation across predefined weight groups, including assessment of the effect of HIV status.

    Time frame: Sparse PK sampling at Weeks 2, 8, and 26 after randomisation; intensive PK sampling at Week 2, pre-dose and 1, 2, 4, 8, and 24 hours post-dose.

  2. Model-derived delpazolid Cmax

    Model-derived delpazolid maximum plasma concentration (Cmax) will be estimated from the final population pharmacokinetic model in participants receiving the MDR-END Plus regimen. This exposure metric will be used to support dose evaluation across predefined weight groups, including assessment of the effect of HIV status.

    Time frame: Sparse PK sampling at Weeks 2, 8, and 26 after randomisation; intensive PK sampling at Week 2, pre-dose and 1, 2, 4, 8, and 24 hours post-dose.

Other outcomes

  1. Time to sustained culture conversion

    Time from randomisation to sustained sputum culture conversion among participants with a positive baseline sputum culture, assessed using liquid media. Sustained sputum culture conversion is defined as two consecutive negative sputum cultures collected at least 7 days apart, with the date of conversion defined as the date of collection of the first negative culture.

    Time frame: From randomisation to the date of first documented sustained sputum culture conversion, assessed during the intended treatment period up to 18 months after randomisation.

  2. Two-month culture conversion rate

    Proportion of participants with a positive baseline sputum culture who achieve culture conversion at 2 months after randomisation, assessed using liquid media.

    Time frame: 2 months after randomisation

  3. Four-month culture conversion rate

    Proportion of participants with a positive baseline sputum culture who achieve culture conversion at 4 months after randomisation, assessed using liquid media.

    Time frame: 4 months after randomisation

  4. Treatment success at end of treatment

    Proportion of participants with treatment success, defined as cured or treatment completed, at the end of the intended treatment period.

    Time frame: At the end of the intended treatment period, assessed up to 20 months after randomisation.

  5. Relapse after treatment success

    Proportion of participants who achieve treatment success and subsequently experience TB or rifampicin-resistant TB relapse within 12 months after treatment discontinuation, as well as time to relapse.

    Time frame: Within 12 months after treatment discontinuation

  6. All-cause mortality

    All-cause mortality rate and time to death from randomisation to the end of the 12-month follow-up period after treatment discontinuation.

    Time frame: From randomisation to 12 months after treatment discontinuation

  7. Other safety endpoints

    Incidence of specific adverse events occurring during treatment and up to 90 days after treatment discontinuation, including Grade 3 or higher adverse drug reactions, serious adverse drug reactions, and adverse events of special interest. Adverse events of special interest include QTcF \>500 ms, increase from baseline in QTcF \>60 ms, Grade 3 or higher hepatotoxicity, and oxazolidinone-related adverse drug reactions.

    Time frame: During treatment and up to 90 days after treatment discontinuation

07

Study locations

2 sites
  • Perinatal HIV Research Unit, PHRU-Matlosana, Tshepong Hospital
    Klerksdorp, North West 2571, South Africa
  • Desmond Tutu TB Centre, Brooklyn Chest Hospital Trial Unit
    Cape Town, Western Cape 7405, South Africa
    • Vikesh Naidoo · Contactdttcregulatory@sun.ac.za · +27-65-811-9528
    • Jennifer Hughes, MBBCh · Contactjhughes@sun.ac.za
    • Jennifer Hughes, MBBCh · Principal investigator
    • Anneke Hesseling, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in this study will be made available. This includes participant-level data required to reproduce the primary and secondary outcomes, as well as associated data dictionaries. All data will be anonymized in accordance with applicable data protection regulations, including the Protection of Personal Information Act (POPIA) of South Africa.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available beginning 12 months following publication of the primary study results or completion of the study, whichever occurs first, and will remain available.

Access criteria: Requests must include a methodologically sound research proposal and will be subject to review and approval by the sponsor and local investigators. Data may be shared under a data access agreement, ensuring compliance with ethical standards, participant confidentiality, and applicable regulatory requirements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jun 2032, 68 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 30, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jun 2032
CompletionEst.
Jun 2032
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07675954
Collaborators
Seoul National University, Korea University, National Institute of Health, Korea, Desmond Tutu TB Centre, Perinatal HIV Research Unit of the University of the Witswatersrand
Responsible party
Jae-Joon Yim (professor, Seoul National University Hospital) — Principal investigator
First posted
Jun 30, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jun 2032 (estimated)
Completion
Jun 2032 (estimated)
Last update
Jun 30, 2026

Study contacts

Jae-Joon Yim, MD, PhD
Contact
yimjj@snu.ac.kr
+82-2-2072-4029
Young Ran Kim, RN, CRA
Contact
oohri31@gmail.com
+82-10-3588-5145
Jeongha Mok, MD, PhD
study director · Pusan National University Hospital
Jennifer Hughes, MBBCh
principal investigator · Desmond Tutu TB Centre, Stellenbosch University
Jae-Joon Yim, MD, PhD
study chair · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion